Home » Stocks » IDXG

Interpace Biosciences, Inc. (IDXG)

Stock Price: $4.58 USD 0.48 (11.71%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Pre-market: $4.30 -0.28 (-6.11%) Jan 20, 9:02 AM
Market Cap 18.51M
Revenue (ttm) 26.45M
Net Income (ttm) -33.55M
Shares Out 4.03M
EPS (ttm) -8.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $4.58
Previous Close $4.10
Change ($) 0.48
Change (%) 11.71%
Day's Open 4.33
Day's Range 4.15 - 4.70
Day's Volume 96,883
52-Week Range 2.84 - 10.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective Decemb...

GlobeNewsWire - 2 months ago

PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications...

GlobeNewsWire - 2 months ago

 Study Demonstrates Superior Performance of ThyGeNEXT ® and ThyraMIR ® vs. Other Molecular Tests

GlobeNewsWire - 3 months ago

Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million

InvestorPlace - 3 months ago

Interpace Biosciences (IDXG) news for Wednesday includes a positive audit committee result giving IDXG stock a much-needed boost. The post Interpace Biosciences News: Why IDXG Stock Is Soaring...

GlobeNewsWire - 3 months ago

PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors h...

GlobeNewsWire - 5 months ago

 Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting

Seeking Alpha - 6 months ago

Interpace Biosciences, Inc. (IDXG) CEO Jack Stover on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

First Quarter Net Revenue Improved Over 53% to $9.2 Million

GlobeNewsWire - 8 months ago

In-Network Access for More Than 3 Million Members

GlobeNewsWire - 8 months ago

Conference Call and Webcast Wednesday April 22, 2020 5:00 pm ET

Benzinga - 9 months ago

Interpace Biosciences (NASDAQ: IDXG) provides complex molecular analysis for the early diagnosis and treatment of cancer.

GlobeNewsWire - 10 months ago

Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue C...

GlobeNewsWire - 10 months ago

In-Network Access for More Than 3 Million Members

GlobeNewsWire - 10 months ago

Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the com...

GlobeNewsWire - 11 months ago

Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbur...

GlobeNewsWire - 11 months ago

PARSIPPANY, NJ, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Ron ...

24/7 Wall Street - 1 year ago

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be anoth...

Other stocks mentioned: CGEN, GLUU, GME, GRPN, MEET, OGI, RTIX, SYBX, ZNGA
Seeking Alpha - 1 year ago

Underappreciated Drivers, Bargain Valuation, And Cash Infusion Set Interpace Up For Substantial Upside

Seeking Alpha - 1 year ago

Underappreciated Drivers, Bargain Valuation & Cash Infusion Set Interpace Up For Substantial Upside

GlobeNewsWire - 1 year ago

Reverse Stock Split Planned Concurrent with Closing

GlobeNewsWire - 1 year ago

Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subs...

GlobeNewsWire - 1 year ago

Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local co...

GlobeNewsWire - 1 year ago

Further Strengthens Business Development Team with Key Hire

GlobeNewsWire - 1 year ago

PARSIPPANY, NJ, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics...

Seeking Alpha - 1 year ago

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date

GlobeNewsWire - 1 year ago

Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR®

GlobeNewsWire - 1 year ago

PARSIPPANY, NJ, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89...

GlobeNewsWire - 1 year ago

Interpace hosts 2nd Annual Fellow Programs

GlobeNewsWire - 1 year ago

PARSIPPANY, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Amper...

GlobeNewsWire - 1 year ago

PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by ...

GlobeNewsWire - 1 year ago

In-Network Access for Thyroid Assays for More than 5 Million Members

GlobeNewsWire - 1 year ago

PARSIPPANY, NJ, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcomi...

GlobeNewsWire - 1 year ago

PARSIPPANY, NJ, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announ...

GlobeNewsWire - 1 year ago

PARSIPPANY, NJ, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcom...

Seeking Alpha - 1 year ago

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q4 2018 Results - Earnings Call Transcript

About IDXG

Interpace Biosciences provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expressi... [Read more...]

Industry
Diagnostics & Research
IPO Date
May 20, 1998
CEO
Nancy Lurker
Employees
176
Stock Exchange
NASDAQ
Ticker Symbol
IDXG
Full Company Profile

Financial Performance

In 2019, IDXG's revenue was $24.22 million, an increase of 10.61% compared to the previous year's $21.90 million. Losses were -$26.74 million, 110.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for IDXG stock is "Buy." The 12-month stock price forecast is 10.13, which is an increase of 121.18% from the latest price.

Price Target
$10.13
(121.18% upside)
Analyst Consensus: Buy